TerminatedInterventionalPhase 1Phase 2Last updated Feb 5, 2020

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

A Phase 1B/2, Multicenter, Open-Label, Safety, and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Overview

ClinicalTrials.gov ID: NCT03075904
Lead Sponsor: Alexion Pharmaceuticals, Inc.INDUSTRY
Brief Summary: This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).
Study Type: Interventional

Status

Study Record Dates

NCT05501717Active, not recruiting

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

NCT05307978Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

NCT03643627Completed

A Study of SYNT001 in Healthy Volunteers

NCT07352423Recruiting

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants

NCT03075878Terminated

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

NCT04920370Completed

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects